Life Scientist > Biotechnology

Treating asthma with stem cells

17 October, 2016

Cynata Therapeutics has received positive data from a proof-of-concept study of its Cymerus mesenchymal stem cells (MSCs) in an experimental model of asthma.


Epilepsy drug now available for tonic-clonic seizures

13 October, 2016

Fycompa, a once-daily epilepsy treatment, is now available in Australia for adjunctive treatment of primary generalised tonic-clonic (PGTC) seizures in adults and adolescents with idiopathic generalised epilepsy.


International BioFest 2016 is coming to Melbourne

12 October, 2016

From 24–27 October 2016, Melbourne Convention Centre will play host to International BioFest — a series of three major life sciences conferences taking place at the one time.


New venture capital fund for Australian healthcare start-ups

11 October, 2016

BioScience Managers has announced the launch of a new venture capital fund for Australia's innovative healthcare and biomedical research sectors.


A potent antioxidant from apples and water

10 October, 2016

A scientist from the University of Newcastle has developed what is claimed to be the most potent dietary antioxidant available anywhere in the world.


Peanut allergy treatment gets a $15 million boost

06 October, 2016

OneVentures will lead a $15 million funding round for a promising new treatment for peanut allergy in children, developed at the Murdoch Childrens Research Institute.


Titratable sleep apnoea device cleared by FDA

28 September, 2016

Oventus Medical has received clearance from the US FDA for the O2Vent T device, an oral appliance intended to alleviate snoring and obstructive sleep apnoea.


Australian CF drug approved in Russia

28 September, 2016

Cystic fibrosis drug Bronchitol, from Pharmaxis, has been approved for marketing in Russia for the treatment of both paediatric and adult CF patients.


Just add water: on-demand pharmaceutical manufacturing

26 September, 2016

US researchers have been working on a molecular manufacturing method that can produce a broad range of biomolecules anywhere in the world, without power or refrigeration.


Most innovative biotech company announced

23 September, 2016

Swiss biotech company BioLingus has been selected as the 2016 winner of The CEO Magazine's Most Innovative Biotech Company award.


Duchenne muscular dystrophy drug approved by FDA

22 September, 2016

The US FDA has announced the approval of a Western Australian-developed drug to treat Duchenne muscular dystrophy (DMD) — a rare and fatal muscle wasting disease affecting one in 3500 boys worldwide.


Making drug development less secretive could lead to quicker, cheaper therapies

15 September, 2016 by Matthew Todd, University of Sydney and Alice Williamson, University of Sydney

With the right investment, an open source drug discovery system — based on sharing all information in the public domain in real time — might compete with the traditional pharmaceutical industry to deliver the drugs we need.


Sartorius Stedim Biotech Connect Upstream bioprocessing platform

11 September, 2016

Sartorius Stedim Biotech (SSB) has developed an innovative and fully integrated technology platform to meet the requirements of today's upstream bioprocessing.


PPS to treat viral joint pain and arthritis

08 September, 2016

Paradigm Biopharmaceuticals and Griffith University have announced pentosan polysulfate sodium (PPS) as a potential breakthrough in the treatment for alphavirus-induced arthralgia and arthritis.


R&D Tax Incentive cuts proposed

05 September, 2016

AusBiotech is not happy with some of the savings measures included in the Omnibus Savings Bill — specifically, the proposed cuts to the Research & Development (R&D) Tax Incentive.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd